Repositioning Candidate Details
| Candidate ID: | R0054 |
| Source ID: | DB00154 |
| Source Type: | investigational; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Dihomo-gamma-linolenic acid |
| Synonyms: | (8Z,11Z,14Z)-Icosatrienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoic acid; 20:3, n-6,9,12 all-cis; 8,11,14-Eicosatrienoic Acid; 8c,11c,14c-eicosatrienoic acid; all-cis-8,11,14-eicosatrienoic acid; all-cis-8,11,14-icosatrienoic acid; all-cis-eicosa-8,11,14-trienoic acid; all-cis-icosa-8,11,14-trienoic acid; C20:3, n-6,9,12 all-cis; cis,cis,cis-8,11,14-eicosatrienoic acid; DGLA; dihomo-γ-linolenic acid; eicosa-8Z,11Z,14Z-trienoic acid; gamma-Homolinolenic acid; Homo-gamma-linolenic acid |
| Molecular Formula: | C20H34O2 |
| SMILES: | CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O |
| Structure: |
|
| DrugBank Description: | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. |
| CAS Number: | 1783-84-2 |
| Molecular Weight: | 306.4828 |
| DrugBank Indication: | For nutritional supplementation, also for treating dietary shortage or imbalance |
| DrugBank Pharmacology: | Dihomo gamma-linolenic acid or DHLA is an n-6 (omega-6) polyunsaturated fatty acid. It is comprised of 20 carbon atoms and three double bonds. DHLA is a byproduct of the 18 carbon gamma-linolenic acid (GLA). DHLA is then converted into prostaglandin E1 (PGE1). PGE1 inhibits platelet aggregation and also exerts a vasodilatory effect. |
| DrugBank MoA: | DHLA (or DGLA) is a precursor in the synthesis of prostaglandin E1 (PGE1) as well as the series-3 prostaglandins. It also serves as a precursor in the synthesis of eicosapentaenoic acid (EPA). EPA is a precursor of the series-3 prostaglandins, the series-5 leukotrienes and the series-3 thromboxanes. These eicosanoids have anti-thrombogenic, anti-inflammatory and anti-atherogenic properties. PGE1 inhibits platelet aggregation and has a vasodilation action. DHLA has also been shown to reduce the production/activity of tumor necrosis factor alpha. |
| Targets: | Prostaglandin G/H synthase 1 inhibitor; Prostaglandin G/H synthase 2 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 5113 | Nutritional deficiency disease | A nutrition disease that is characterized by deficiency of a nutritional element, such as a vitamin, mineral, carbohydrate, protein, fat, or general energy content. https://medlineplus.gov/malnutrition.html | disease of metabolism/acquired metabolic disease/nutrition disease | Details |